Navigation Links
YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
Date:1/5/2009

edicated to prevent infusion reactions.

About YM BioSciences

YM BioSciences Inc. is a company that identifies, develops and commercializes differentiated products principally in the area of oncology for patients worldwide. The Company is developing nimotuzumab, a humanized monoclonal antibody, and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. Nimotuzumab is in development targeting multiple tumour types in combination with radiation, chemoradiation and chemotherapy. The drug, which is approved for marketing in a number of countries, is significantly differentiated from all other currently marketed EGFR-targeting agents because of a remarkably benign side-effect profile. In more than 3,500 patients reported as having been treated worldwide, to date, no Grade III/IV incidents of rash or radiation dermatitis haves been described and reports of any of the other side-effects that are typical of EGFR-targeting molecules have been rare. AeroLEF(R) is in development for the treatment of moderate to severe pain, including cancer pain. The product completed a randomized trial in 2007 and is being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the C
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... DIEGO, Dec. 15 Aethlon Medical, Inc. ... Dr. Jeff Schorey and Dr. Wayne Comper ... Exosome Sciences, Inc. (ESI). Both Dr. Schorey and ... field. ESI, a wholly owned subsidiary of Aethlon ... that the Hemopurifier®, a medical device being advanced ...
(Date:12/15/2009)... -- The Center for Business Intelligence (CBI), ... to announce the full agenda for the ... Congress . The forum will take place ... 2010. ,, Over 1,500 senior-level Finance, Accounting, ... premier event since its inception, and this ...
(Date:12/14/2009)... and THOUSAND OAKS, Calif., Dec. 14 ... Amgen Inc.(Nasdaq: AMGN ) today announced that ... worldwide rights to Array,s small-molecule glucokinase activator program, ... 1 clinical trial in patients with Type 2 ... the agreement, Array will receive an upfront payment ...
(Date:12/14/2009)... Scientific Corporation (NYSE: BSX ) today announced ... aggregate principal amount of its senior notes under the ... of $850 million of 4.50 percent notes due January ... 2020 and $300 million of 7.375 percent notes due ... net proceeds for general corporate purposes, including prepaying its ...
Breaking Biology Technology:Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 2Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 4Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 5CBI Announces the Agenda for Their 6th Annual Pharmaceutical/Biotech Accounting and Reporting Congress 2Array BioPharma and Amgen Partner in Type 2 Diabetes 2Array BioPharma and Amgen Partner in Type 2 Diabetes 3Array BioPharma and Amgen Partner in Type 2 Diabetes 4Array BioPharma and Amgen Partner in Type 2 Diabetes 5Array BioPharma and Amgen Partner in Type 2 Diabetes 6Array BioPharma and Amgen Partner in Type 2 Diabetes 7Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3
... and KENILWORTH, N.J., Nov. 6 Centocor,Inc., ... today that an estimated one million patients ... leading anti-tumor necrosis,factor (TNF)-alpha therapy worldwide. In ... patients worldwide than all other anti-TNF-alpha agents,combined. ...
... and VALAIS, Switzerland, Nov. 5 ,Lantibio, Inc. and TRB ... a subsidiary of Alcon, Inc. (NYSE: ACL ) ... Eye Syndrome product. The,product consists of a TRB patented ... the US under an IND by a,subsidiary of Lantibio. ...
... to 3Q06 to $43.5 Million in 3Q07 -,- 3Q07 Net Income Increased 58% ... ... - Company Provides Financial Outlook for 2007 and ... AOB ), a leading manufacturer and distributor of,plant-based pharmaceutical and nutraceutical products, today ...
Other Biology Technology:REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 2REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 3REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 4REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 5REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 6REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 7REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 8REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 9REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 10REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 11REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 12Lantibio and TRB Chemedica Announce Licensing Agreement with Alcon for US Development and Marketing of Dry Eye Drug 2Lantibio and TRB Chemedica Announce Licensing Agreement with Alcon for US Development and Marketing of Dry Eye Drug 3Lantibio and TRB Chemedica Announce Licensing Agreement with Alcon for US Development and Marketing of Dry Eye Drug 4American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 2American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 3American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 4American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 5American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 6American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 7American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 8
(Date:12/15/2009)... San Diego, California, has been awarded an accreditation ... on results of a recent onsite inspection. ... this national recognition and congratulated for the "excellence ... GenWay Clinical Laboratory is one of nearly 7,000 ... Program, begun in the early 1960s, is recognized ...
(Date:12/15/2009)... is available in German ., Despite ... across the globe, cultures vary as to how space ... not use egocentric terms such as ,left, right, front, ... notions like ,north, south, east, west, at all times ... bowl" or "There is an snake by your Northern ...
(Date:12/15/2009)... In the near future, consumers can look forward ... such as laptops, PDAs and mobile phones. This ... energy harvesting technologies which are critical elements for ... devices and systems. , Analog IC design is ... energy harvesting. To pre-position the nation in advanced ...
Breaking Biology News(10 mins):More than a jump to the left 2NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 2NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 3Doctors Join Patients to Protest at Health Care Freedom Tea Parties July 17 3B Thousands Join in Nationwide Event 51910 1Dow AgroSciences NemGenix Establish New Collaboration in Plant Biotechnology 13065 1Dow AgroSciences NemGenix Establish New Collaboration in Plant Biotechnology 13065 2Branded Surgery Is Not Always the 26quot 3BQuick Fix 26quot 3B it is Advertised To Be 51902 1Branded Surgery Is Not Always the 26quot 3BQuick Fix 26quot 3B it is Advertised To Be 51902 2Branded Surgery Is Not Always the 26quot 3BQuick Fix 26quot 3B it is Advertised To Be 51902 3
... found that fresh water systems from across the northeastern United ... and the White Mountains of New Hampshire are becoming saltier ... Not only are there more roads, but the amount of ... fresh water systems reports Sujay Kaushal and colleagues in ...
... mild to moderate depression, say researchers in this week's ... which shows how human health and wellbeing are dependent ... study was carried out in Honduras and involved 30 ... assigned to the experimental group and half to the ...
... a wound in certain plants like roses and grapevines develop ... common soil bacterium that is able to "smell" the wound ... Steve Winans says that the pathogen Agrobacterium tumefaciens ... infection, which can slip into the plant's cells and their ...
Other Biology News:Fresh water affected by salt from deicing roads 2Swimming with dolphins can alleviate depression 2Plant wounds trigger bacteria 2